Biodexa Pharmaceuticals plc - American Depositary Shares (BDRX)
2.9900
+0.1900 (6.79%)
Biodexa Pharmaceuticals is a biopharmaceutical company focused on advancing innovative therapies for the treatment of cancer and other serious diseases
The company specializes in developing proprietary drug delivery systems designed to enhance the therapeutic efficacy of existing drugs while minimizing side effects. By leveraging its expertise in nanomedicine and targeted delivery technologies, Biodexa strives to create safer, more effective treatment options to improve patient outcomes in oncology and beyond.
CARDIFF, UK / ACCESS Newswire / February 12, 2025 / Biodexa Pharmaceuticals PLC. (NASDAQBDRX), a clinical-stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, received Fast Track status from the U.S. Food and Drug Administration for eRapa, a proprietary encapsulated form of rapamycin being developed for the treatment of familial adenomatous polyposis (FAP). The news follows Biodexa reporting positive 12-month data from a phase 2 clinical trial in July 2024, as previously covered by Benzinga.
The drug, a proprietary encapsulated form of rapamycin, is being developed for familial adenomatous polyposis (FAP), a condition that, if left untreated, universally leads to colorectal cancer.
CARDIFF, UK / ACCESSWIRE / November 21, 2024 / Biodexa Pharmaceuticals PLC (NASDAQBDRX), an acquisition-focused clinical-stage biopharmaceutical company focused on developing treatments for unmet medical needs, has made significant progress in transforming itself from a drug delivery innovator to a therapeutics company with a focus on drugs to fight diabetes and cancer.
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Biodexa Pharmaceuticals Plc (“Biodexa” or “the Company”) (NASDAQBDRX). Investors who purchased Biodexa securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/BDRX.
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Biodexa Pharmaceuticals Plc (“Biodexa” or “the Company”) (NASDAQBDRX). Investors who purchased Biodexa securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/BDRX.
Biodexa Pharmaceuticals reports updates from the MAGIC-1 study on MTX110 for recurrent glioblastoma. MTX110 has also demonstrated potential in treating diffuse midline glioma, a rare brain cancer, with significant improvements in survival rates in Phase 1 trials.
Biodexa Pharmaceuticals shares are soaring in Tuesday's after-hours session after the company announced it was granted an extension to demonstrate compliance with Nasdaq listing requirements.
